
BlossomHill Therapeutics, Inc. (NASDAQ:BLSM – Free Report) – HC Wainwright cut their FY2026 earnings per share (EPS) estimates for BlossomHill Therapeutics in a report issued on Monday, November 16th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($5.27) per share for the year, down from their prior estimate of ($4.75). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for BlossomHill Therapeutics’ current full-year earnings is ($5.80) per share. HC Wainwright also issued estimates for BlossomHill Therapeutics’ Q4 2026 earnings at ($0.90) EPS.
A number of other brokerages have also commented on BLSM. Guggenheim upped their price target on BlossomHill Therapeutics from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Leerink Partners raised their price objective on shares of BlossomHill Therapeutics from $36.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, September 21st. Weiss Ratings assumed coverage on shares of BlossomHill Therapeutics in a research note on Tuesday, November 3rd. They issued a “sell (e-)” rating on the stock. Lifesci Capital started coverage on shares of BlossomHill Therapeutics in a research report on Tuesday, September 1st. They set an “outperform” rating and a $32.00 target price on the stock. Finally, Zacks Research upgraded shares of BlossomHill Therapeutics to a “hold” rating in a research note on Wednesday, September 2nd. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, BlossomHill Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $35.00.
BlossomHill Therapeutics Trading Down 1.2%
Shares of NASDAQ BLSM opened at $14.41 on Wednesday. The stock has a 50 day simple moving average of $17.39. BlossomHill Therapeutics has a 12 month low of $11.02 and a 12 month high of $27.99.
BlossomHill Therapeutics (NASDAQ:BLSM – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($0.93) by ($0.36).
BlossomHill Therapeutics Company Profile
BlossomHill Therapeutics is a biotechnology company focused on developing medicines for cancer. Its research has centered on targeted small-molecule treatments designed to address cancer-related genetic changes. The company’s pipeline has included BH-306, an investigational inhibitor of mutant IDH1 being developed for cancers associated with that mutation. The program is in development and is not a marketed treatment. Publicly available information about the company’s leadership and geographic operations is limited.
Read More
- Five stocks we like better than BlossomHill Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
